Form 4: Intra-Cellular Therapies CEO Sharon Mates Exercises Options and Sells Shares Under 10b5-1 Plan

Sharon Mates, CEO of Intra-Cellular Therapies, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sharon Mates, the Chairman and CEO of Intra-Cellular Therapies, Inc., has reported transactions involving the company's common stock.
• On August 21, 2024, Mates exercised stock options to acquire 53,013 shares at a price of $17.57 per share and sold 44,134 shares at a weighted average price of $75.4026, 4,297 shares at a weighted average price of $76.2001, 2,682 shares at a weighted average price of $77.2139 and 1,900 shares at a weighted average price of $77.9805.
• On August 22, 2024, Mates exercised stock options to acquire 39,380 shares at a price of $17.57 per share and sold 35,011 shares at a weighted average price of $74.5787 and 4,369 shares at a weighted average price of $75.4697.
• On August 23, 2024, Mates exercised stock options to acquire 28,680 shares at a price of $17.57 per share and sold 28,680 shares at a weighted average price of $74.4573.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2024.
• Following these transactions, Mates directly owns 1,070,329 shares of Intra-Cellular Therapies, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, but the sale of shares by the CEO could raise some concerns among investors.

Positives

• The CEO's exercise of stock options indicates confidence in the company's future prospects.
• The sales were conducted under a pre-arranged trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Market fluctuations could impact the value of the remaining shares held by the CEO.
• Investor sentiment could be affected by the CEO's decision to sell a portion of their holdings, even under a 10b5-1 plan.

Industry Context

Executive stock option exercises and sales are common in the pharmaceutical industry as part of compensation packages and personal financial planning.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are generally benchmarked against peer companies in the biotechnology and pharmaceutical sectors.
• Companies like Eli Lilly, Pfizer, and AbbVie also have executives who periodically exercise options and sell shares, often under similar 10b5-1 plans.
• The specific amounts and timing of these transactions vary based on individual circumstances and company performance.

Stakeholder Impact

• Shareholders may react to the CEO's share sales, although the pre-planned nature of the transactions should mitigate concerns.
• The company's reputation could be affected by the perception of insider activity, although the Rule 10b5-1 plan provides a legal framework for the transactions.

Key Dates